Gupta, S. K., Kizilbash, S. H., Carlson, B. L., Mladek, A. C., Boakye-Agyeman, F., Bakken, K. K., . . . Sarkaria, J. N. (2015). Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma. J Natl Cancer Inst.
シカゴスタイル引用形Gupta, Shiv K., et al. "Delineation of MGMT Hypermethylation As a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma." J Natl Cancer Inst 2015.
MLA引用形式Gupta, Shiv K., et al. "Delineation of MGMT Hypermethylation As a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma." J Natl Cancer Inst 2015.
警告: この引用は必ずしも正確ではありません.